Table 3.

Clinical and immunological outcomes

Patient No.	Baseline				At 8 weeks				At 16 weeks
	threshold, mL	casein-specific IgE, IUA/mL	casein-specific IgG4, IUA/mL	casein BAL, %	threshold, mL	casein-specific IgE, IUA/mL	casein-specific IgG4, IUA/mL	casein BAL, %	threshold, mL	casein-specific IgE, IUA/mL	casein-specific IgG4, IUA/mL	casein BAL, %
pHF-pHF group
1	0.35	260.0	15,763	NR	1.85	283.0	9,512	NR	0.80	266.0	14,286	NR
2	8.50	178.0	7,980	44.4	14.00	224.0	4,449	19.9	1.80	212.0	5,669	63.2
3	1.80	75.7	2,775	NR	4.00	110.0	2,965	NR	9.00	110.0	3,044	NR
4	0.00	32.5	558	15.9	0.80	30.9	282	13.2	0.80	31.6	259	19.4
5	0.00	13.0	1,621	25.7	1.80	11.3	1,263	63.2	4.00	12.0	1,360	52.0
6	0.80	>500	2,723	NR	1.80	>500	3,400	NR	0.80	>500	3,628	NR
7	0.00	29.2	<200	30.1	0.00	29.5	<200	28.5	0.30	26.2	<200	77.3
8	0.80	3.1	3,064	13.1	9.00	2.3	1,529	12.7	20.00	2.8	1,392	58.0
9	4.00	106.0	920	91.1	20.00	91.0	691	81.9	20.00	86.1	687	77.5
10	9.00	147.0	11,573	NR	4.00	137.0	12,197	NR	3.50	110.0	12,624	NR
Median	0.80	90.9	2,749	27.9	2.93	100.5	2,247	24.2	2.65	98.1	2,218	60.6
eHF-pHF group
11	8.50	82.1	4,368	82.3	8.50	68.1	4,312	67.6	3.50	64.0	5,009	90.7
12	1.50	26.2	365	NR	0.50	20.9	390	NR	20.00	27.5	484	NR
13	4.00	425.0	14,254	67.6	1.80	464.0	18,853	94.0	9.00	347.0	17,104	7.6
14	4.00	17.8	1,146	NR	9.00	11.0	1,429	NR	4.00	10.8	2,329	NR
15	0.00	127.0	46,212	24.5	4.00	140.0	42,648	54.1	9.00	56.2	25,319	79.1
16	9.00	94.8	972	59.9	9.00	76.5	370	40.3	4.00	86.2	519	60.5
17	0.80	71.7	<200	70.6	0.80	38.9	<200	68.5	9.00	28.1	<200	93.3
18	8.50	18.9	739	64.3	20.00	14.4	543	83.5	4.00	12.0	635	68.2
19	4.00	14.3	1,048	63.9	9.00	13.4	658	46.2	9.00	11.7	539	53.8
20	1.80	n.a.	n.a.	n.a.	9.00	n.a.	n.a.	n.a.	4.40	n.a.	n.a.	n.a.
Median	4.00	71.7	1,048	64.3	8.75	38.9	658	67.6	6.70	28.1	635	68.2

BAL, basophil activation level; n.a., not applicable; NR, nonresponder.